KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Change in Receivables (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Change in Receivables data on record, last reported at $4.8 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 359.92% year-over-year to $4.8 million; the TTM value through Dec 2025 reached $7.9 million, up 187.16%, while the annual FY2025 figure was $7.9 million, 187.16% up from the prior year.
  • Change in Receivables reached $4.8 million in Q4 2025 per PACB's latest filing, up from -$1.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $10.8 million in Q1 2023 and bottomed at -$6.3 million in Q1 2024.
  • Average Change in Receivables over 5 years is $918650.0, with a median of $453500.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: surged 720.0% in 2021, then crashed 1445.76% in 2022.
  • A 5-year view of Change in Receivables shows it stood at $295000.0 in 2021, then plummeted by 1445.76% to -$4.0 million in 2022, then surged by 254.38% to $6.1 million in 2023, then tumbled by 130.33% to -$1.9 million in 2024, then skyrocketed by 359.92% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $4.8 million in Q4 2025, -$1.6 million in Q3 2025, and $612000.0 in Q2 2025.